“Abrupt” reductions in antidepressant treatment “ranging from 20 percent to 50 percent” Increases in psychotropic drug ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Psilocybin-assisted psychotherapy significantly improved a range of psychiatric symptoms among people with cancer, according ...

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s ...

LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line ...

Blood clots are a well-established risk of estrogen therapy in women, particularly for those with clotting disorders. The ...

Hawaii’s Senate has approved a proposal to create a special fund that would support clinical research into psychedelic-assisted treatment using substances such as psilocybin and MDMA, both of which ...

Gorgas, President and CEO of Artelo Biosciences. “Notably, enrollment in our Phase 1 study of ART26.12, a Fatty Acid Binding Protein (FABP) inhibitor, has progressed rapidly and is expected to ...